Peer Reviewed Publications

Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Gupta S, Hensley PJ, Li R, Choudhury A, Daneshmand S, Faltas BM, Flaig TW, Grass GD, Grivas P, Hansel DE, Hassanzadeh C, Kassouf W, Kukreja J, Mendoza-Valdés A, Moschini M, Mouw KW, Navai N, Necchi A, Rosenberg JE, Ross JS, Siefker-Radtke AO, Taylor J, Willliams SB, Zlotta AR, Buckley R, Kamat AM. Eur Urol. 2025 Apr 22:S0302-2838(25)00189-7. doi: 10.1016/j.eururo.2025.03.017. PMID: 40268594 

Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG). Contieri R, Soloway MS, Gontero P, Herr H, Kassouf W, Mertens LS, Moschini M, O’Donnell M, Palou J, Psutka SP, Rouprêt M, Teoh JYC, Kamat AM. Eur Urol Oncol. 2025 Feb;8(1):179-189. doi: 10.1016/j.euo.2024.08.001. Epub 2024 Aug 31. PMID: 39218742 

Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. Li R, Hensley PJ, Gupta S, Al-Ahmadie H, Babjuk M, Black PC, Brausi M, Bree KK, Fernández MI, Guo CC, Horowitz A, Lamm DL, Lerner SP, Lotan Y, Mariappan P, McConkey D, Mertens LS, Mir C, Ross JS, O’Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess PE, Svatek RS, Tan WS, Taoka R, Buckley R, Kamat AM. Eur Urol. 2024 Dec;86(6):516-527. doi: 10.1016/j.eururo.2024.08.001. Epub 2024 Aug 24. PMID: 39183090

Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. * with SITC
Kamat AM, Apolo AB, Babjuk M, Bivalacqua TJ, Black PC, Buckley R, Campbell MT, Compérat E, Efstathiou JA, Grivas P, Gupta S, Kurtz NJ, Lamm D, Lerner SP, Li R, McConkey DJ, Palou Redorta J, Powles T, Psutka SP, Shore N, Steinberg GD, Sylvester R, Witjes JA, Galsky MD. J Clin Oncol. 2023 Dec 10;41(35):5437-5447. doi: 10.1200/JCO.23.00307. Epub 2023 Oct 4. PMID: 37793077 

Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries. * with WBCPC
Makaroff LE, Filicevas A, Boldon S, Hensley P, Black PC, Chisolm S, Demkiw S, Fernández MI, Sugimoto M, Jensen BT, Witjes WPJ, Bagshaw K, Cirefice-Funk L, Knight A, Kamat AM. Eur Urol. 2023 Aug;84(2):248-251. doi: 10.1016/j.eururo.2023.04.034. Epub 2023 May 24. PMID: 37236857 

International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance. Tan WS, Contieri R, Buffi NM, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat AM. J Urol. 2023 Nov;210(5):763-770. doi: 10.1097/JU.0000000000003639. Epub 2023 Aug 3. PMID: 37535836

International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. Roumiguié M, Kamat AM, Bivalacqua TJ, Lerner SP, Kassouf W, Böhle A, Brausi M, Buckley R, Persad R, Colombel M, Lamm D, Palou-Redorta J, Soloway M, Brothers K, Steinberg G, Lotan Y, Sylvester R, Alfred Witjes J, Black PC. Eur Urol. 2021 Dec 23:S0302-2838(21)02213-2

Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG) Matulay JT, Soloway M, Witjes JA, Buckley R, Persad R, Lamm DL, Boehle A, Palou J, Colombel M, Brausi M, Kamat AM. . BJU Int. 2020; 125:497-505.

Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. Mostafid H, Babjuk M, Bochner B, Lerner SP, Witjes F, Palou J, Roupret M, Shariat S, Gontero P, van Rhijn B, Zigeuner R, Sylvester R, Comperat E, Burger M, Malavaud B, Soloway M, Williams S, Black P, Daneshmand S, Steinberg G, Brausi M, Catto J, Kamat AM.  Eur Urol. 2020 Jun;77(6):669-670.

BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Kamat AM, Colombel M, Sundi D, Lamm D, Boehle A, Brausi M, Buckley R, Persad R, Palou J, Soloway M, Witjes JA.  Nat Rev Urol. 2017; 14:244-255.

* Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA.  J Clin Oncol. 2016;34:1935-44

Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer.  Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R, Buckley R, Böhle A, Colombel M, Palou J. J Urol 2014;192:305-15.

Defining progression in non-muscle invasive bladder cancer: it is time for a new, standard definition. Lamm D, Persad R, Brausi M, Buckley R, Witjes JA, Palou J, Böhle A, Kamat AM, Colombel M, Soloway M. J Urol 2014;191:20-7.

Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, Persad R, Buckley R, Colombel M, Böhle A.  BJU Int 2013;112:742-50.

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. Brausi M, Witjes JA, Kamat AM, Lamm D, Persad R, Palou J, Colombel M, Buckley R, Soloway M, Akaza H, Böhle A.  J Urol 2011;186:2158-67.

Maintenance bacillus Calmette-Guérin: the standard of care for the prophylaxis and management of intermediate- and high-risk non-muscle invasive bladder cancer. Lamm D, Persad R, Colombel M, Brausi M.  Eur Urol Suppl 2010;9:715-34.

Epidemiology, staging, grading and risk stratification of bladder cancer. Colombel M, Soloway M, Akaza H, Böhle A, Palou J, Buckley R, Lamm D, Brausi M, Witjes JA, Persad R. Eur Urol Suppl 2008;7:618-26.

Diagnosis of non-muscle invasive bladder cancer. Palou J, Böhle A, Witjes JA, Colombel M, Brausi M, Lamm D, Persad R, Buckley R, Akaza H, Soloway M.  Eur Urol Suppl 2008;7:627-36.

Current approaches to the management of non-muscle invasive bladder cancer: comparison of current guidelines and recommendations. Persad R, Lamm D, Brausi M, Soloway M, Palou J, Böhle A, Colombel M, Akaza H, Buckley R, Witjes JA. Eur Urol Suppl 2008;7:637-50.

Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Lamm D, Colombel M, Persad R, Soloway M, Böhle A, Palou J, Witjes JA, Akaza H, Buckley R, Brausi M. Eur Urol Suppl 2008;7:651-66.

Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Witjes JA, Palou J, Soloway M, Lamm D, Brausi M, Spermon JR, Persad R, Buckley R, Akaza H, Colombel M, Böhle A. Eur Urol Suppl 2008;7:667-74.